ESCMID Postgraduate Education Course

Viral Hepatitis: Recent Advances in Diagnosis and Treatment

Istanbul, Turkey
28 Feb – 1 Mar 2014

ESCMID Postgraduate Education Course

Viral Hepatitis: Recent Advances in Diagnosis and Treatment

Istanbul, Turkey
28 Feb – 1 Mar 2014

Scientific picture outside: Signs of an icteric patient

Contact

Contact Person
Prof Hakan Leblebicioglu
Department of Infectious Diseases & Clinical Microbiology
Ondokuz Mayis University Medical School
Samsun, Turkey
Phone +90 533 566 31 38
Fax +90 362 457 60 14
hakanomu@yahoo.com

Administrative Secretariat
Hakkı Pehlivan
Humanitas MICE
Cumhuriyet Caddesi No: 105 / 734373
Elmadag/İstanbul, Turkey
Phone +90 212 247 29 49
Fax +90 212 247 42 57
escmid@humanitastour.com.tr

Target Audience
50 – 100 infectious disease and clinical microbiology specialists and trainees, gastroenterologists and clinicians taking care of patients with viral hepatitis.

Faculty Members
C. Agalar, Istanbul, Turkey
U. S. Akarca, Izmir, Turkey
J. E. Arends, Utrecht, The Netherlands
G. Di Perri, Torino, Italy
H. Erdem, Istanbul, Turkey
V. Ghisetti, Torino, Italy
A. Hoepelman, Utrecht, The Netherlands
S. Hosoglu, Diyarbakir, Turkey
W. Irving, Nottingham, United Kingdom
C. Karaca, Istanbul, Turkey
Z. Karasu, Izmir, Turkey
S. Kaymakoğlu, İstanbul, Turkey
B. Kilani, Tunis, Tunisia
Z. Kocak Tufan, Ankara, Turkey
I. Koksal, Trabzon, Turkey
K. Kumbasar, Istanbul, Turkey
A. Mangia, San Giovanni Rotondo, Italy
R. Ozaras, İstanbul, Turkey
D. Salmon, Paris, France
F. Tabak, İstanbul, Turkey
V. Turhan, İstanbul, Turkey
H. Vahaboglu, İstanbul, Turkey

Organisers
• ESCMID Study Group for Viral Hepatitis (ESGVH)
• Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD)
• Turkish Viral Hepatitis Society (VHSD)

Course Coordinator
• Hakan Leblebicioglu, Samsun, Turkey

Course Objectives
• Increase knowledge about viral hepatitis
• Review the epidemiology, prevention and outcome of viral hepatitis
• Enhance attendees’ understanding of diagnosis of hepatitis
• Increase knowledge about the treatment of viral hepatitis and follow-up
• Demonstrate all the steps of diagnosis and treatment of chronic viral hepatitis through case discussions
Friday, 28 February 2014

09:00 Opening session

How to deal with guidelines for hepatitis C treatment
Chair: F. Tobak & C. Hezode
09:15 Boceprevir and Telaprevir based triple therapy: guide to guidelines. U. S. Akarca
09:45 Management of patients with non-1 genotypes. A. Mangia
10:15 Management of acute HCV infection. A. Hoepelman
10:45 Coffee break

Challenges from a new era in hepatitis C treatment
Chair: V. Vahaboglu & D. Salmon
11:00 Management of side effects of Telaprevir and Boceprevir. Z. Kocak Tufan
11:30 Pharmacogenomics and drug-drug interaction in the treatment of HCV chronic hepatitis. G. Di Perri
12:00 Hepatitis C treatment in developing countries: economic perspectives. R. Ozaras
12:30 Lunch

Future HCV treatment
Chair: S. Kaymakoglu & B. Kilani
13:30 Anti HCV treatment: what’s coming in the next years. J. E. Arends
14:00 Pre-treatment and on-treatment predictors for decisions of anti HCV therapy. W. Irving
14:30 Round table: case studies (3 groups and rotate)*
14:30 Treatment of chronic hepatitis C in HIV-infected patients in the era of direct acting antivirals. D. Salmon
15:00 Coffee break
15:15 Difficult to treat patient 1: the multi-experienced patient, cirrhosis. C. Hezode
15:45 Difficult to treat patient 2: cryoglobulinaemia, thrombocytopenia, renal disease, congenital anaemia. A. Hoepelman

Saturday, 1 March 2014

Hepatitis B
Chairs: C. Agalar & J. E. Arends
09:00 Hepatitis B in the immunosuppressed patient. D. Salmon
09:30 Treatment of HBV in HIV infected patients. H. Kumbasar
10:00 Pregnancy and chronic hepatitis. V. Leblebicioglu
10:30 Coffee break

Diagnostic workshop (3 groups and rotate)
10:45 Molecular diagnosis of chronic hepatitis. V. Ghisetti
11:15 HBs Ag: new life for an old marker. V. Turhan
11:45 Non-invasive assessment of fibrosis. I. Koksal
12:15 Lunch

Hepatitis A and E
Chairs: H. Erdem & V. Ghisetti
13:30 Epidemiology of HEV. H. Dalton
14:00 Virology of HEV. W. Irving
14:30 HEV in immunocompromised hosts and pregnant women. B. Kilani
15:00 Coffee break

Other hepatitis issues
Chairs: C. Karaca & W. Irving
15:15 Indications and waiting list management in liver transplantation. Z. Karasu
15:45 Can we stop chronic hepatitis B treatment? R. Ozaras
16:15 What’s new in delta hepatitis? S. Hosoglu
16:45 Closing session

* Round table case studies: case presentations with closed questions on 2 or 3 clinical turning points voted by the audience and discussed by the experts